iSpecimen Inc. 8-K — AI Bull & Bear Analysis

The filing presents a company at a crossroads, balancing a necessary capital injection and regulatory victory against systemic governance failures. While the restoration of Nasdaq compliance and the $2.5 million raise provide immediate stability, the underlying dilution from warrants and the failure to secure a quorum for annual meetings raise questions about long-term stability. Investors must weigh the ability of the company to leverage its new marketing budget against the risk of further equity dilution and persistent management instability.